Last reviewed · How we verify
Omadacycline tablets
At a glance
| Generic name | Omadacycline tablets |
|---|---|
| Sponsor | Paratek Pharmaceuticals Inc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections (PHASE1)
- Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc) (PHASE2)
- Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia (PHASE3)
- Microbiome Effect of Omadacycline on Healthy Volunteers (PHASE1)
- A Study to Compare the Effect of Omadacycline Versus Moxifloxacin in Healthy Adult Volunteers (PHASE1)
- Pharmacokinetics of Omadacycline in Cystic Fibrosis (PHASE4)
- Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia (PHASE1)
- Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Omadacycline tablets CI brief — competitive landscape report
- Omadacycline tablets updates RSS · CI watch RSS
- Paratek Pharmaceuticals Inc portfolio CI